Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Unknown 2

Sponsor Class

OTHER 23INDUSTRY 22NIH 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 126Breast 26Head & Neck 17Other solid neoplasm 11Genitourinary 11Gynecologic 8Thoracic 3Lymphoid 3Tumor-Agnostic 2Other hematologic neoplasm 2CNS 2Endocrine 1Dermatologic 1

Conditions

Neoplasms, Unknown Primary 2

Interventions

Specimen Handling 19Biopsy 18Magnetic Resonance Spectroscopy 12Paclitaxel 9trastuzumab deruxtecan 4olaparib 4X-Rays 4Taxes 4nilotinib 3Radiotherapy 3Gemcitabine 3Cisplatin 3Carboplatin 3Bevacizumab 3trametinib 2talazoparib 2pembrolizumab 2omipalisib 2durvalumab 2copanlisib 2aldesleukin 2Vincristine 2Topotecan 2Phantoms, Imaging 2Leucovorin 2Immunoglobulin G 2Fluorouracil 2Doxorubicin 2Disulfides 2Cyclophosphamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Fluorouracil × Tumor-Agnostic × Clear all
NCT00022178 2013-09-20

Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin

National Cancer Institute (NCI)

Phase 3 Unknown
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00003558 2013-08-07

Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin

National Cancer Institute (NCI)

Phase 3 Unknown
140 enrolled
Tumor-Agnostic

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡